                         SEQUENCE LISTING

<110>  MIREXUS BIOTECHNOLOGIES INC.
 
<120>  COMPOUNDS FOR SENSITIZING CANCER CELLS TO A CHEMOTHERAPEUTIC DRUG

<130>  55727555-25PCT

<150>  US63/130944
<151>  2020-12-28

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  1
cagccatggg ctgggac                                                      17


<210>  2
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  2
cttcagctct gacaccgaca                                                   20


<210>  3
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  3
aaactcatga gcagtctgca                                                   20


<210>  4
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  4
aggagatctt cagtttcgga gg                                                22


<210>  5
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  5
gaaagcagtt agcaaggaaa gg                                                22


<210>  6
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  6
gacatatact ccatgtaggg aagtg                                             25


<210>  7
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  7
ggagattaga tcctgaggaa aacca                                             25


<210>  8
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  8
aacggaagat gaatctcagt gcta                                              24


<210>  9
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  9
ctggcaccca gcacaatg                                                     18


<210>  10
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  primer sequence

<400>  10
ccgatccaca cggagtactt g                                                 21







<


